文献速递头颈部肿瘤放疗放疗物理与技术

磁共振引导下复发及第二原发头颈部肿瘤再程放疗

Magnetic resonance imaging guided reirradiation of recurrent and second primary head and neck cancer.
PubMed 文献 · Adv Radiat Oncol · 2017-02-21

单中心前瞻性登记研究纳入13例既往放疗>60 Gy后复发或新发头颈部鳞癌患者,采用0.35-T磁共振引导放疗系统再程放疗。1年和2年野内控制率均为72%,2年总生存率53%、无进展生存率59%,无治疗相关死亡或住院,并发症以皮肤脱屑、吞咽痛等为主。

要点

  • MRI引导再程放疗对复发/第二原发头颈癌显示有效疾病控制,2年野内控制率72%。
  • 2年总生存率53%、无进展生存率59%,无治疗相关死亡或住院。
  • 并发症包括皮肤脱屑、吞咽痛、外耳炎、角膜炎/结膜炎及1例吸入性肺炎。

核心结论

  • MRI引导放疗再程治疗复发及第二原发头颈部肿瘤可获得有效疾病控制且并发症相对较低。

研究设计与样本

  • 采用0.35-T MRI扫描仪与钴-60放射源组成的ViewRay系统行MRI引导再程放疗。
  • 放疗方式为常规分割调强放疗中位剂量66 Gy或立体定向体部放疗7–8 Gy/次非连续日照射中位剂量40 Gy,2例(17%)接受同步化疗。

主要发现

  • 1年和2年野内控制率估计均为72%。
  • 2年总生存率和无进展生存率估计分别为53%和59%。
  • 共获取227次每日MRI扫描用于引导再程放疗。
  • 无治疗相关死亡或住院,并发症包括皮肤脱屑、吞咽痛、外耳炎、角膜炎和/或结膜炎及1例吸入性肺炎。

临床怎么用

  • 对既往放疗>60 Gy后复发或新发头颈部鳞癌患者,可考虑采用MRI引导放疗行再程放疗。
  • MRI软组织分辨率优势可能提高治疗增益比,但需结合患者具体情况评估。

局限性

  • 单中心小样本前瞻性登记研究,共13例患者。
  • 随访时间有限,报告为初步结果。
  • 仅2例(17%)接受同步化疗,治疗方案异质性可能影响结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report a single-institutional experience using magnetic resonance imaging (MRI) guided radiation therapy for the reirradiation of recurrent and second cancers of the head and neck. METHODS AND MATERIALS: Between October 2014 and August 2016, 13 consecutive patients with recurrent or new primary cancers of the head and neck that occurred in a previously irradiated field were prospectively enrolled in an institutional registry trial to investigate the feasibility and efficacy of MRI guided radiation therapy using a 0.35-T MRI scanner with a cobalt-60 radiation therapy source called the ViewRay system (ViewRay Inc., Cleveland, OH). Eligibility criteria included biopsy-proven evidence of recurrent or new primary squamous cell carcinoma of the head and neck, measurable disease, and previous radiation to >60 Gy. MRI guided reirradiation was delivered either using intensity modulated radiation therapy with conventional fractionation to a median dose of 66 Gy or stereotactic body radiation therapy (SBRT) using 7 to 8 Gy fractions on nonconsecutive days to a median dose of 40 Gy. Two patients (17%) received concurrent chemotherapy. RESULTS: The 1- and 2-year estimates of in-field control were 72% and 72%, respectively. A total of 227 daily MRI scans were obtained to guide reirradiation. The 2-year estimates of overall survival and progression-free survival were 53% and 59%, respectively. There were no treatment-related fatalities or hospitalizations. Complications included skin desquamation, odynophagia, otitis externa, keratitis and/or conjunctivitis, and 1 case of aspiration pneumonia. CONCLUSIONS: Our preliminary findings show that reirradiation with MRI guided radiation therapy results in effective disease control with relatively low morbidity for patients with recurrent and second primary cancers of the head and neck. The superior soft tissue resolution of the MRI scans that were used for planning and delivery has the potential to improve the therapeutic ratio.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen AM, Cao M, Hsu S, et al. Magnetic resonance imaging guided reirradiation of recurrent and second primary head and neck cancer. Adv Radiat Oncol. 2017. PMID: 28740928. doi:10.1016/j.adro.2017.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。